Chemistry:MYCO-004

From HandWiki

MYCO-004 is a patch-delivered psychedelic tryptamine which is under development for the treatment of psychiatric disorders.[1][2][3] It is anticipated to allow for precision dosing and to have a short duration of approximately 2 hours.[4] The drug is being developed by Mydecine.[1][2] As of December 2021, it is in preclinical research for psychiatric disorders.[1][2] The exact chemical structure of MYCO-004 does not yet seem to have been disclosed.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "MYCO 004". 15 December 2021. https://adisinsight.springer.com/drugs/800061733. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on MYCO-004 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/a54046b04f70467c9756b36ecae7f58c. 
  3. ↑ Psychedelic Alpha (10 January 2022). "Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds". https://psychedelicalpha.com/news/mydecine-achieves-innovative-supercomputing-artificial-intelligence-modeling-in-psychedelic-drug-development-enabling-quick-screening-of-billions-of-compounds. "The Company’s AI program has already led to identifying promising enhancements to psilocybin and psilocin which they have included in their recent patent application around MYCO-004, which directly addresses further precision in delivery control and shelf stabilization through a dermal route of administration." 
  4. ↑ Psychedelic Alpha (24 June 2021). "Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004". https://psychedelicalpha.com/news/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MYCO-004&oldid=4032622"